{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T03:21:42Z","timestamp":1769224902891,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1038\/s41409-019-0661-7","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T16:06:24Z","timestamp":1568822784000},"page":"376-383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["High dose chemotherapy and autologous hematopoietic cell transplantation for Wilms tumor: a study of the European Society for Blood and Marrow Transplantation"],"prefix":"10.1038","volume":"55","author":[{"name":"On behalf of EBMT Paediatric Diseases Working Party","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Spreafico","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Dalissier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"P\u00f6tschger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Michon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0369-8515","authenticated-orcid":false,"given":"C.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4462-5523","authenticated-orcid":false,"given":"G.","family":"Bisogno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Yeomanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Willasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"van den Heuvel Eibrink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2248-323X","authenticated-orcid":false,"given":"N.","family":"Graf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Dallorso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,18]]},"reference":[{"key":"661_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(13)70548-5","volume":"15","author":"G Gatta","year":"2014","unstructured":"Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood cancer survival in Europe 1999\u20132007: results of EUROCARE-5 a population-based study. Lancet Oncol. 2014;15:35\u201347.","journal-title":"Lancet Oncol"},{"key":"661_CR2","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1016\/j.ejca.2012.06.007","volume":"48","author":"N Graf","year":"2012","unstructured":"Graf N, Van Tinteren H, Bergeron C, Pein F, van den Heuvel-Eibrink MM, Sandstedt B, et al. Characteristics and outcome of stage II and III non-anaplastic Wilms\u2019 tumour treated according to the SIOP trial and study 93-01. Eur J Cancer. 2012;48:3240\u201348.","journal-title":"Eur J Cancer"},{"key":"661_CR3","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/S0140-6736(14)62395-3","volume":"386","author":"K Pritchard-Jones","year":"2015","unstructured":"Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM, Acha T, Godzinski J, et al. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms\u2019 tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet. 2015;386:1156\u201364.","journal-title":"Lancet"},{"key":"661_CR4","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/JCO.2015.66.1140","volume":"34","author":"EJ Gratias","year":"2016","unstructured":"Gratias EJ, Dome JS, Jennings LJ, Chi YY, Tian J, Anderson J, et al. Association of chromosome 1q gain with inferior survival in favorable-histology Wilms Tumor: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2016;34:3189\u201394.","journal-title":"J Clin Oncol"},{"key":"661_CR5","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.juro.2017.06.081","volume":"5","author":"F Spreafico","year":"2017","unstructured":"Spreafico F, Biasoni D, Lo Vullo S, Gandola L, D\u2019Angelo P, Terenziani M, et al. Results of the third AIEOP cooperative protocol on Wilms tumor (TW2003) and related considerations. J Urol. 2017;5:1138\u201345.","journal-title":"J Urol"},{"key":"661_CR6","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1470-2045(18)30293-6","volume":"19","author":"J Brok","year":"2018","unstructured":"Brok J, Lopez-Yurda M, Tinteren HV, Treger TD, Furtw\u00e4ngler R, Graf N, et al. Relapse of Wilms\u2019 tumour and detection methods: a retrospective analysis of the 2001 Renal Tumour Study Group-International Society of Paediatric Oncology Wilms\u2019 tumour protocol database. Lancet Oncol. 2018;19:1072\u201381.","journal-title":"Lancet Oncol"},{"key":"661_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/pbc.20822","volume":"48","author":"DM Green","year":"2007","unstructured":"Green DM, Cotton CA, Malogolowkin M, Breslow NE, Perlman E, Miser J, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer. 2007;48:493\u20139.","journal-title":"Pediatr Blood Cancer"},{"key":"661_CR8","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/pbc.21267","volume":"50","author":"M Malogolowkin","year":"2008","unstructured":"Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer. 2008;50:236\u201341.","journal-title":"Pediatr Blood Cancer"},{"key":"661_CR9","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1586\/era.09.159","volume":"9","author":"F Spreafico","year":"2009","unstructured":"Spreafico F, Pritchard-Jones K, Malogolowkin MH, Bergeron C, Hale J, de Kraker J, et al. Treatment of relapsed Wilms tumors: lessons learned. Expert Rev Anticancer Ther. 2009;9:1807\u201315.","journal-title":"Expert Rev Anticancer Ther"},{"key":"661_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ejca.2017.04.005","volume":"79","author":"J Brok","year":"2017","unstructured":"Brok J, Pritchard-Jones K, Geller JI, Spreafico F. Review of phase I and II trials for Wilms\u2019 tumour\u2014can we optimise the search for novel agents? Eur J Cancer. 2017;79:205\u201313.","journal-title":"Eur J Cancer"},{"key":"661_CR11","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1200\/JCO.1998.16.10.3295","volume":"16","author":"F Pein","year":"1998","unstructured":"Pein F, Michon J, Valteau-Couanet D, Quintana E, Frappaz D, Vannier JP, et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms\u2019 tumor: a French Society of Pediatric Oncology study. J Clin Oncol. 1998;16:3295\u2013301.","journal-title":"J Clin Oncol"},{"key":"661_CR12","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/sj.bmt.1703771","volume":"30","author":"B Kremens","year":"2002","unstructured":"Kremens B, Gruhn B, Klingebiel T, Hasan C, Laws HJ, Koscielniak E, et al. High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transpl. 2002;30:893\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"661_CR13","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1200\/JCO.2004.09.073","volume":"22","author":"AD Campbell","year":"2004","unstructured":"Campbell AD, Cohn SL, Reynolds M, Seshadri R, Morgan E, Geissler G, et al. Treatment of relapsed Wilms\u2019 tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children\u2019s Memorial Hospital. J Clin Oncol. 2004;22:2885\u201390.","journal-title":"J Clin Oncol"},{"key":"661_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/pbc.21524","volume":"51","author":"F Spreafico","year":"2008","unstructured":"Spreafico F, Bisogno G, Collini P, Jenkner A, Gandola L, D\u2019Angelo P, et al. Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem-cell support: experience by the Italian Association of Pedaitric Hematology and Oncology. Pediatr Blood Cancer. 2008;51:23\u20138.","journal-title":"Pediatr Blood Cancer"},{"key":"661_CR15","unstructured":"Hale J, Hobson R, Moroz V, Sartori P. Results of UK Children\u2019s Cancer and Leukemia Group (CCLG) protocol for relapsed Wilms tumor (UKWR): unified relapse strategy improves outcome. In: 40th meeting of International Society of Paediatric Oncology. 2008;O154:62."},{"key":"661_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/annonc\/mdf028","volume":"13","author":"AM Abu-Ghosh","year":"2002","unstructured":"Abu-Ghosh AM, Krailo MD, Goldman SC, Slack RS, Davenport V, Morris E, et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms\u2019 tumor: a Children\u2019s Cancer group report. Ann Oncol. 2002;13:460\u20139.","journal-title":"Ann Oncol"},{"key":"661_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ejca.2012.07.010","volume":"49","author":"TC Ha","year":"2013","unstructured":"Ha TC, Spreafico F, Graf N, Dallorso S, Dome JS, Malogolowkin M, et al. An international strategy to determine the role of high dose therapy in recurrent Wilms\u2019 tumour. Eur J Cancer. 2013;49:194\u2013210.","journal-title":"Eur J Cancer"},{"key":"661_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/mpo.2950220103","volume":"22","author":"A Garaventa","year":"1994","unstructured":"Garaventa A, Hartmann O, Bernard JL, Zucker JM, Pardo N, Castel V, et al. Autologous bone marrow transplantation for pediatric Wilms\u2019 tumour: the experience of the European Bone Marrow Transplantation Solid Tumour Registry. Med Pediatr Oncol. 1994;22:11\u20134.","journal-title":"Med Pediatr Oncol"},{"key":"661_CR19","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/bmt.2017.178","volume":"52","author":"MH Malogolowkin","year":"2017","unstructured":"Malogolowkin MH, Hemmer MT, Le-Rademacher J, Hale GA, Metha PA, Smith AR, et al. Outcomes following autologous hematopoietic stem cell transplant for patients with relapsed Wilms\u2019 tumor: a CIBMTR retrospective analysis. Bone Marrow Transpl. 2017;52:1549\u201355.","journal-title":"Bone Marrow Transpl"},{"key":"661_CR20","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/nrurol.2017.163","volume":"14","author":"MM van den Heuvel-Eibrink","year":"2017","unstructured":"van den Heuvel-Eibrink MM, Hol JA, Pritchard-Jones K, van Tinteren H, Furtw\u00e4ngler R, Verschuur AC, et al. Position paper: rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol. Nat Rev Urol. 2017;14:743\u201352.","journal-title":"Nat Rev Urol"},{"key":"661_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"661_CR22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"D. R. Cox","year":"1972","unstructured":"Cox D. Regression models and life table. J R Stat Soc Ser B Stat Methodol. 1972;34:187\u2013220.","journal-title":"Journal of the Royal Statistical Society: Series B (Methodological)"},{"key":"661_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2307\/3001968","volume":"6","author":"F Wilcoxon","year":"1945","unstructured":"Wilcoxon F. Individual comparisons by ranking methods. Biom Bull. 1945;6:80\u20133.","journal-title":"Biom Bull"},{"key":"661_CR24","doi-asserted-by":"crossref","unstructured":"Kalbfleisch JD, Prentice RL. Wiley Series in Probability and Statistics. The statistical analysis of failure time data. 2nd ed. 2002; John Wiley and Sons.","DOI":"10.1002\/9781118032985"},{"key":"661_CR25","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141\u201354.","journal-title":"Ann Stat"},{"key":"661_CR26","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1200\/JCO.2015.62.1888","volume":"33","author":"JS Dome","year":"2015","unstructured":"Dome JS, Graf N, Geller JI, Fernandez CV, Mullen EA, Spreafico F, et al. Advances in Wilms tumor treatment and biology: progress through international collaboration. J Clin Oncol. 2015;33:2999\u20133007.","journal-title":"J Clin Oncol"},{"key":"661_CR27","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/pbc.25357","volume":"62","author":"AM Mavinkurve-Groothuis","year":"2015","unstructured":"Mavinkurve-Groothuis AM, van den Heuvel-Eibrink MM, Tytgat GA, van Tinteren H, Vujanic G, Pritchard-Jones KL, et al. Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG). Pedia Blood Cancer. 2015;62:598\u2013602.","journal-title":"Pedia Blood Cancer"},{"issue":"2","key":"661_CR28","doi-asserted-by":"publisher","first-page":"e26849","DOI":"10.1002\/pbc.26849","volume":"65","author":"Janna A. Hol","year":"2017","unstructured":"Hol JA, van den Heuvel-Eibrink MM, Graf N, Pritchard-Jones K, Brok J, van Tinteren H, et al. Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group. Pediatr Blood Cancer. 2018;65. https:\/\/doi.org\/10.1002\/pbc.26849 .","journal-title":"Pediatric Blood & Cancer"},{"key":"661_CR29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/00043426-200203000-00007","volume":"24","author":"JS Dome","year":"2002","unstructured":"Dome JS, Liu T, Krasin M, Lott L, Shearer P, Daw NC, et al. Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children\u2019s Research Hospital. Hosp J Pediatr Hematol\/Oncol. 2002;24:192\u20138.","journal-title":"Hosp J Pediatr Hematol\/Oncol"},{"key":"661_CR30","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1586\/era.09.45","volume":"9","author":"F Spreafico","year":"2009","unstructured":"Spreafico F, Pritchard-Jones K, Bergeron C, de Kraker, Dallorso S, Graf N. Value and difficulties of a common European strategy for recurrent Wilms\u2019 tumor. Expert Rev Anticancer Ther. 2009;9:693\u20136.","journal-title":"Expert Rev Anticancer Ther"},{"key":"661_CR31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/cjp2.77","volume":"3","author":"J Wegert","year":"2017","unstructured":"Wegert J, Vokuhl C, Ziegler B, Ernestus K, Leuschner I, Furtw\u00e4ngler R, et al. TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia. J Pathol Clin Res. 2017;3:234\u201348.","journal-title":"J Pathol Clin Res"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0661-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0661-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0661-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T18:37:05Z","timestamp":1721759825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-019-0661-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,18]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["661"],"URL":"https:\/\/doi.org\/10.1038\/s41409-019-0661-7","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,18]]},"assertion":[{"value":"5 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}